Safety and dose modification for patients receiving niraparib

Niraparib is a poly(ADP-ribose) polymerase inhibitor approved in the USA and Europe for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. In the pivotal ENGOT...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2018-08, Vol.29 (8), p.1784-1792
Hauptverfasser:	Berek, J.S., Matulonis, U.A., Peen, U., Ghatage, P., Mahner, S., Redondo, A., Lesoin, A., Colombo, N., Vergote, I., Rosengarten, O., Ledermann, J., Pineda, M., Ellard, S., Sehouli, J., Gonzalez-Martin, A., Berton-Rigaud, D., Madry, R., Reinthaller, A., Hazard, S., Guo, W., Mirza, M.R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Body Weight dose modification Dose-Response Relationship, Drug Female Humans Incidence Indazoles - administration & dosage Indazoles - adverse effects Maintenance Chemotherapy - adverse effects Maintenance Chemotherapy - methods Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality ovarian cancer Ovarian Neoplasms - blood Ovarian Neoplasms - drug therapy Ovarian Neoplasms - mortality PARP inhibitor Piperidines - administration & dosage Piperidines - adverse effects Platelet Count Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage Poly(ADP-ribose) Polymerase Inhibitors - adverse effects Progression-Free Survival Retrospective Studies Risk Factors safety thrombocytopenia Thrombocytopenia - blood Thrombocytopenia - chemically induced Thrombocytopenia - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!